CN Patent

CN101503399B — C-芳基葡萄糖苷sglt2抑制剂

Assigned to Massachusetts Egret LLC · Expires 2012-06-27 · 14y expired

What this patent protects

本发明涉及一种通式I所示的C-芳基葡萄糖苷衍生物，其用途以及组合物。所述的C-芳基葡萄糖苷衍生物具有极其优异的抑制SGLT的效果。本发明化合物可以单独或者与其它抗糖尿病药物或其它治疗剂联合使用，可用于预防或治疗糖尿病以及相关疾病。

USPTO Abstract

本发明涉及一种通式I所示的C-芳基葡萄糖苷衍生物，其用途以及组合物。所述的C-芳基葡萄糖苷衍生物具有极其优异的抑制SGLT的效果。本发明化合物可以单独或者与其它抗糖尿病药物或其它治疗剂联合使用，可用于预防或治疗糖尿病以及相关疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN101503399B
Jurisdiction
CN
Classification
—
Expires
2012-06-27
Drug substance claim
No
Drug product claim
No
Assignee
Massachusetts Egret LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.